4/13
07:00 am
enta
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
Low
Report
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
4/7
07:00 am
enta
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
Low
Report
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
3/30
07:24 am
enta
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) [Yahoo! Finance]
Neutral
Report
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) [Yahoo! Finance]
3/30
07:00 am
enta
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
Neutral
Report
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
3/26
09:00 am
enta
Enanta Pharmaceuticals (ENTA) is now covered by Rodman & Renshaw. They set a "buy" rating and a $20.00 price target on the stock.
Low
Report
Enanta Pharmaceuticals (ENTA) is now covered by Rodman & Renshaw. They set a "buy" rating and a $20.00 price target on the stock.
3/15
06:50 pm
enta
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference [Yahoo! Finance]
Medium
Report
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference [Yahoo! Finance]
3/3
07:00 am
enta
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
Low
Report
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
2/10
08:05 am
enta
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
2/10
07:13 am
enta
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting [Yahoo! Finance]
2/10
07:00 am
enta
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
Low
Report
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
2/9
07:06 pm
enta
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
2/9
04:16 pm
enta
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot [Yahoo! Finance]
2/9
04:01 pm
enta
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
Low
Report
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025